Results 71 to 80 of about 2,911,119 (244)

Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.

PLoS ONE, 2013
Receptor tyrosine kinases (RTKs), in response to their growth factor ligands, phosphorylate and activate downstream signals important for physiological development and pathological transformation.
Ramesh Narayanan, Muralimohan Yepuru, Christopher C Coss, Zhongzhi Wu, Matthew N Bauler, Christina M Barrett, Michael L Mohler, Yun Wang, Juhyun Kim, Linda M Snyder, Yali He, Nelson Levy, Duane D Miller, James T Dalton   +13 more
doaj   +1 more source

Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts : implications for neuromodulation [PDF]

, 2010
Copyright © 2010 the authorsBrain-derived neurotrophic factor (BDNF) signaling is critical for neuronal development and transmission. Recruitment of TrkB receptors to lipid rafts has been hown to be necessary for the activation of specific signaling ...
Assaife-Lopes, Natália, Chao, Moses V., Pereira, Daniela B., Ribeiro, Joaquim A., Sebastião, Ana M, Sousa, Vasco C.   +5 more
core   +1 more source

Withdrawal pain following patients discontinuing Trk inhibitors [PDF]

Journal of Oncology Pharmacy Practice
Objective This article aims to expand on the existing literature regarding the incidence of withdrawal pain following discontinuation of Trk inhibitors and to explore strategies that mitigate this withdrawal pain. Data Source A retrospective observational study was conducted among patients who were at least 18 years-old or older and had documentation ...
Alan Chin, Sheila Lindsay, Emily K Bergsland, Hyunseok Kang   +3 more
openaire   +3 more sources

Diagnostic challenges and successful organ‐preserving therapy in a case of secretory carcinoma of minor salivary glands

Cancer Reports, 2022
Background Secretory carcinoma is a more recently described subtype of salivary gland carcinoma that may pose diagnostic challenges and frequently harbors NTRK fusions that may successfully be targeted by TRK inhibitors in advanced disease.
Ruben Bill, Daniel G. Deschler, Mikael J. Pittet, Sara I. Pai, Peter M. Sadow, Jong Chul Park   +5 more
doaj   +1 more source

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer [PDF]

Cancer Discovery, 2016
Abstract Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of ...
RUSSO, MARIANGELA, MISALE, SANDRA, Wei, Ge, SIRAVEGNA, GIULIA, CRISAFULLI, GIOVANNI, LAZZARI, LUCA, Corti, Giorgio, Rospo, Giuseppe, Novara, Luca, Mussolin, Benedetta, Bartolini, Alice, Cam, Nicholas, Patel, Roopal, Yan, Shunqi, Shoemaker, Robert, Wild, Robert, DI NICOLANTONIO, Federica, Sartore Bianchi, Andrea, Li, Gang, Siena, Salvatore, BARDELLI, Alberto   +20 more
openaire   +2 more sources

Age-Dependency of Neurite Outgrowth in Postnatal Mouse Cochlear Spiral Ganglion Explants

Brain Sciences, 2020
Background: The spatial gap between cochlear implants (CIs) and the auditory nerve limits frequency selectivity as large populations of spiral ganglion neurons (SGNs) are electrically stimulated synchronously.
Claudia Frick, Stefan Fink, Dominik Schmidbauer, Francis Rousset, Holger Eickhoff, Anke Tropitzsch, Benedikt Kramer, Pascal Senn, Rudolf Glueckert, Helge Rask-Andersen, Karl-Heinz Wiesmüller, Hubert Löwenheim, Marcus Müller   +12 more
doaj   +1 more source

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion

Clinical Case Reports, 2021
Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer.
Fabián Pitoia
doaj   +1 more source

Neuroprotektion und Aktivierung von Neurotrophin-Signaltransduktionswegen durch Hemmung von Protein-Tyrosin-Phosphatasen und durch NO-Donatoren [PDF]

, 2004
Trotz des enormen Fortschrittes der Medizin und neuen Erkenntnissen über die pathologischen Mechanismen des neuronalen Zelltodes steht bislang keine wirkungsvolle, kausale Therapie zur Behandlung neurodegenerativer Erkrankungen zur ...
Gerling, Norbert, Krieglstein, Josef (Prof. Dr. Dr.)   +1 more
core   +1 more source

BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors

npj Precision Oncology
Aberrant activation of tropomyosin receptor kinases (TRKs) is a well-defined oncogenic driver for neurotrophic tropomyosin receptor kinase (NTRK)-fusion cancers, and acquired resistant mutations have emerged with clinical use of the first-generation TRK ...
Jin Sheng, Hong Chen, Bang Fu, Hongming Pan, Jiabing Wang, Weidong Han   +5 more
doaj   +1 more source

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach [PDF]

, 2018
Background: TRK fusion cancer results from gene fusions involving NTRK1, NTRK2 or NTRK3. Larotrectinib, the first selective TRK inhibitor, has demonstrated an overall response rate (ORR) of 75% with a favorable safety profile in the first 55 ...
Albert, C. M., Berlin, J. D., Bielack, S. S., Cox, M. C., Cruickshank, S., Doz, F., Drilon, A., Dubois, S. G., Federman, N., Geoerger, B., Hong, D. S., Ku, N. C., Kummar, S., Lassen, U. N., Mascarenhas, L., McDermott, R., Oh, D. Y., Schilder, R. J., Tan, D. S., van Tilburg, C. M.   +19 more
core   +1 more source